首页> 外国专利> Compositions comprising cd19xcd3 bispecific antibodies for the treatment of tumorous mass of lymph node tissue and/or extranodal lymphoma caused by diffuse large b cell lymphoma (dlbcl)

Compositions comprising cd19xcd3 bispecific antibodies for the treatment of tumorous mass of lymph node tissue and/or extranodal lymphoma caused by diffuse large b cell lymphoma (dlbcl)

机译:包含cd19xcd3双特异性抗体的组合物,用于治疗由弥漫性大b细胞淋巴瘤(dlbcl)引起的淋巴结组织和/或结外淋巴瘤的肿瘤块

摘要

The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19 x CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, "BiTE") is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
机译:本发明提供了用于治疗弥漫性大B细胞淋巴瘤(DLBCL)的手段和方法。具体而言,双特异性CD19 x CD3抗体是通过其CD3结合部分与T细胞结合,并通过其CD19结合部分与特别是淋巴瘤细胞表面的CD19结合(即双特异性T细胞结合剂“ BiTE”)。用于治疗患者的DLBCL引起的淋巴球组织和/或结外淋巴瘤的肿瘤块。

著录项

  • 公开/公告号IL256110A

    专利类型

  • 公开/公告日2018-08-30

    原文格式PDF

  • 申请/专利权人 AMGEN RESEARCH (MUNICH) GMBH;

    申请/专利号IL20170256110

  • 发明设计人

    申请日2017-12-05

  • 分类号A61K;A61P;C07K;

  • 国家 IL

  • 入库时间 2022-08-21 12:52:25

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号